MultiPlan (NYSE:MPLN – Get Rating) and Nuvei (NASDAQ:NVEI – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Analyst Recommendations
This is a breakdown of current ratings for MultiPlan and Nuvei, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MultiPlan | 0 | 3 | 0 | 0 | 2.00 |
Nuvei | 0 | 1 | 13 | 0 | 2.93 |
MultiPlan presently has a consensus target price of $1.43, indicating a potential upside of 30.30%. Nuvei has a consensus target price of $60.57, indicating a potential upside of 48.13%. Given Nuvei’s stronger consensus rating and higher probable upside, analysts clearly believe Nuvei is more favorable than MultiPlan.
Institutional & Insider Ownership
Risk & Volatility
MultiPlan has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Nuvei has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Profitability
This table compares MultiPlan and Nuvei’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MultiPlan | -53.06% | -2.20% | -0.62% |
Nuvei | 6.73% | 7.91% | 4.51% |
Valuation & Earnings
This table compares MultiPlan and Nuvei’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MultiPlan | $1.08 billion | 0.65 | -$572.91 million | ($0.90) | -1.22 |
Nuvei | $843.32 million | 6.85 | $56.73 million | $0.39 | 104.85 |
Nuvei has lower revenue, but higher earnings than MultiPlan. MultiPlan is trading at a lower price-to-earnings ratio than Nuvei, indicating that it is currently the more affordable of the two stocks.
Summary
Nuvei beats MultiPlan on 12 of the 14 factors compared between the two stocks.
About MultiPlan
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services, which reduce medical costs through data-driven algorithms that detect claims over-charges and recommend or negotiate reimbursement; network-based services that reduce medical costs through contracted discounts with healthcare providers; and payment and revenue integrity services, which reduce medical costs by identifying and removing improper and unnecessary charges paid during the claim. It also provides health benefit plans, which features reference-based pricing and tools to engage health plan members and providers to make the use of benefits before and after care delivery. The company serves national insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, third party administrators, bill review companies, Taft-Hartley plans, and other entities that pay medical bills in the commercial healthcare, government, workers' compensation, and auto medical markets. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.
About Nuvei
Nuvei Corporation provides payment technology solutions to merchants and partners in North America, Europe, the Middle East and Africa, Latin America, and the Asia Pacific. It provides a suite of payment solutions to support lifecycle of a transaction across mobile or in-app, online, unattended, and in-store channels. The company sells and distributes its solutions through direct sales, indirect sales for small-and-medium sized businesses, and eCommerce resellers. Nuvei Corporation was founded in 2003 and is headquartered in Montreal, Canada.
Receive News & Ratings for MultiPlan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MultiPlan and related companies with MarketBeat.com's FREE daily email newsletter.